Long-lasting control with eribulin in a taxane pretreated metastatic breast cancer patient

Research output: Contribution to journalArticle

Abstract

Effective treatment options for patients with metastatic breast cancer resistant to anthracyclines and taxanes are limited. Moreover, many chemotherapeutic agents need to be interrupted due to toxicity. Here we report an extremely long duration of chemotherapy with eribulin (11 courses) in a taxane-pretreated metastatic breast cancer patient. Therapy was well tolerated with no worsening of pre-existing neuropathy, achieving excellent outcomes and a good quality of life. This report adds to the pool of knowledge regarding the use of this important new metastatic breast cancer chemotherapeutic agent.

Original languageEnglish
Pages (from-to)23-26
Number of pages4
JournalFuture Oncology
Volume11
Issue number15s
DOIs
Publication statusPublished - Aug 1 2015

Keywords

  • breast cancer
  • eribulin
  • response

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Long-lasting control with eribulin in a taxane pretreated metastatic breast cancer patient'. Together they form a unique fingerprint.

  • Cite this